The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function

Drug and Alcohol Dependence

Volumn 117, Issue 2-3, 2011, Pages 190-197

  Shmygalev, Sergey ^a   Damm, Martin ^a   Weckbecker, Klaus ^b   Berghaus, Günter ^c   Petzke, Frank ^d   Sabatowski, Rainer ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Buprenorphine; Driving ability; Maintenance therapy; Vienna Test System

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; OPIATE;

ADULT; AGE; ALERTNESS; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRIVING ABILITY; DRUG ABUSE; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MENTAL STRESS; MOTOR COORDINATION; OPIATE ADDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; RESPONSE TIME; SEX DIFFERENCE; SOCIAL BEHAVIOR; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ORIENTATION;

ADULT; ATTENTION; AUTOMOBILE DRIVING; BUPRENORPHINE; CHRONIC DISEASE; COGNITION; CONTROL GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; PSYCHOMOTOR PERFORMANCE; REACTION TIME; TIME FACTORS; VISUAL PERCEPTION;

EID: 79960839717     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.01.017     Document Type: Article

References (50)

1. Baewert A., Gombas W., Schindler S.D., Peternell-Moelzer A., Eder H., Jagsch R., Fischer G. Influence of peak and trough levels of opioid maintenance therapy on driving aptitude. Eur. Addict. Res. 2007, 13(3):127-135.
2. Ball J.C., Corty E. Basic issues pertaining to the effectiveness of methadone maintenance treatment. NIDA Res. Monogr. 1988, 86:178-191.
3. Ball J., Corty E., Bond H., Myers C., Tommasello A. The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res. Monogr. 1988, 81:224-230.
4. Bartl G., Lager F., Domesle L. Test performance with minimal alcoholic intoxication. Blutalkohol 1996, 33(1):1-16.
5. Berghaus, G., 2001. Methadone substitution and driver safety/fitness to drive-an overview of experimental research. Substitution and driving license. Meeting Report. Bavarian Academy of Addiction, Munich, pp. 28-32.
6. Berghaus G. Methadon-substitution and driving fitness/skills related to driving-review on experimental research. Suchtmed 2002, 4(3):169-174.
7. Bernard J.P., Morland J., Krogh M., Khiabani H.Z. Methadone and impairment in apprehended drivers. Addiction 2009, 104(3):457-464.
8. Dagtekin O., Gerbershagen H.J., Wagner W., Petzke F., Radbruch L., Sabatowski R. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth. Anal. 2007, 105(5):1442-1448.
9. Davids E., Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur. Neuropsychopharmacol. 2004, 14(3):209-216.
10. De Gier J.J. Methadone and driving-problems related to driving under the influence of methadone or other substances. Road Traffic and Psychoactive Substances 2004, Council of Europe Pub, Strasbourg, 71-105.
11. Dittert S., Naber D., Soyka M. Methadone substitution therapy and driving. Results of an experimental study. Nervenarzt 1999, 70(5):457-462.
12. Federal Government of Germany Regulation on the admission of persons for road transport and amending road traffic regulations. Federal Law Gazette 1998, pp. 2214-2262.
13. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101(2):275-281.
14. Gaertner J., Radbruch L., Giesecke T., Gerbershagen H., Petzke F., Ostgathe C., Elsner F., Sabatowski R. Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol. Scand. 2006, 50(6):664-672.
15. Galski T., Williams J.B., Ehle H.T. Effects of opioids on driving ability. J. Pain Symptom Manage. 2000, 19(3):200-208.
16. Giacomuzzi S., Haaser W., Pilsz L., Riemer Y. Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. Forensic Sci. Int. 2005, 152(2-3):323-324.
17. Herberg K.W. Antidepressives and traffic safety. Fortschr. Neurol. Psychiatr. 1994, 62(1):24-28.
18. Herberg K.W. Age-related changes in aspects of performance relevant to safety. Eur. J. Geriatr. 2000, 2(1):18-26.
19. Hilgers, R.D., Friedel, B., Berghaus, G., 1997. Testing for equivalence in the studies on driving ability. Berichte der Bundesanstalt für Straßenwesen, Kongressbericht der Deutschen Gesellschaft für Verkehrsmedizin e.V. Wirtschaftsverlag NW, Bremerhaven. M92:130-134.
20. Hill J.L., Zacny J.P. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology 2000, 152(1):31-39.
21. International Council on Alcohol, Drugs and Traffic Safety Guidelines on Experimental Studies Undertaken to Determine a Medicinal Drugós Effect on Driving or Skills Related to Driving 1999, ICADTS, Ontario.
22. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267(20):2750-2755.
23. Kagerer S., Backmund M., Walcher S., Soyka M. Driving performance under maintenance treatment with buprenorphine. Suchtmed 2002, 4(1):17-24.
24. Kendall S.E., Sjøgren P., Pimenta C.A., Højsted J., Kurita G.P. The cognitive effects of opioids in chronic non-cancer pain. Pain 2010, 150(2):225-230.
25. Kroj G. Psychological Assessment Fitness to Drive. Deutscher Psychologenverlag, Bonn 1995.
26. Kurita G.P., Lundorff L., Pimenta C.A. The cognitive effects of opioids in cancer: a systematic review. Support Care Cancer 2009, 17:11-21.
27. Lenne M.G., Dietze P., Rumbold G.R., Redman J.R., Triggs T.J. The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend. 2003, 72(3):271-278.
28. Lewrenz H. Assessment Guidelines for Fitness to Drive 2000, Bremerhaven, Wirtschaftsverlag, NW.
29. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 1984, 40(4):1079-1087.
30. Pergolizzi J., Aloisi A.M., Dahan A., Filitz J., Langford R., Likar R., Mercadante S., Morlion B., Raffa R.B., Sabatowski R., Sacerdote P., Torres L.M., Weinbroum A.A. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010, 10(5):428-450.
31. Rapeli P., Fabritius C., Alho H., Salaspuro M., Wahlbeck K., Kalska H. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin. Pharmacol. 2007, 7:5.
32. Richter R., Hobi V. The impairment of the ability to drive with blood alcohol concentrations of 0.5 per mille-a review of the literature. Schweiz. Med. Wochenschr. 1975, 105(27):884-890.
33. Risser R., Chaloupka Ch., Grundler W., Sommer M., Häusler J., Kaufmann C. Using non-linear methods to investigate the criterion validity of traffic-psychological test batteries. Accid. Anal. Prev. 2008, 40(2008):149-157.
34. Rossler H., Battista H.J., Deisenhammer F., Gunther V., Pohl P., Prokop L., Riemer Y. Methadone-substitution and driving ability. Forensic Sci. Int. 1993, 62(1-2):63-66.
35. Rounsaville B.J., Petry N.M., Carroll K.M. Single versus multiple drug focus in substance abuse clinical trials research. Drug Alcohol Depend. 2003, 70:117-125.
36. Sabatowski R., Schwalen S., Rettig K., Herberg K.W., Kasper S.M., Radbruch L. Driving ability under long-term treatment with transdermal fentanyl. J. Pain Symptom Manage. 2003, 25(1):38-47.
37. Schindler S.D., Orther R., Peternell A., Eder H., Opgenoorth E., Fischer G. Maintenance therapy with synthetic opioids and driving aptitude. Eur. Addict. Res. 2004, 10:80-87.
38. Schuhfried G Manual Expert System Traffic (XPSV), Schuhfried GmbH, Mödling 2009.
39. Schuhfried G. Wiener Testsystem 2010, cited December, Available from: http://www.schuhfried.at/deu/wts/wts_index.htm.
40. Singhal A., Tripathi B.M., Pal H.R., Jena R., Jain R. Effect of buprenorphine on psychomotor functions in patients on buprenorphine maintenance. J. Opioid Manag. 2008, 4(1):41-47.
41. Soyka M., Hock B., Kagerer S., Lehnert R., Limmer C., Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J. Clin. Psychopharmacol. 2005, 25(5):490-493.
42. Specka M., Finkbeiner T., Lodemann E., Leifert K., Kluwig J., Gastpar M. Cognitive-motor performance of methadone-maintained patients. Eur. Addict. Res. 2000, 6(1):8-19.
43. Strumpf M., Köhler A., Zenz M., Willweber-Strumpf A., Dertwinkel R.D. Opioids and driving ability. Schmerz 1997, 11(4):233-240.
44. Strumpf M., Willweber-Strumpf A., Herberg K.W., Zenz M. Safety-relevant performance of patients on chronic opioid therapy. Schmerz 2005, 19(5):426-433.
45. Thapar P., Zacny J.P., Thompson W.A., Apfelbaum J.L. Using alcohol as a standard to assess the degree of impairment induced by sedative and analgesic drugs used in ambulatory surgery. Anaesthesiology 1995, 82(1):53-59.
46. Veldhuijzen D.S., van Wijck A.J., Wille F., Verster J.C., Kenemans J.L., Kalkman C.J., Olivier B., Volkerts E.R. Effect of chronic nonmalignant pain on highway driving performance. Pain 2006, 122(1-2):28-35.
47. Verheul R., van den Brink W. The role of personality pathology in the aetiology and treatment of substance use disorders. Curr. Opin. Psychiatry 2000, 13:163-169.
48. Walker D.J., Zacny J.P. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology 1998, 140:191-201.
49. Zacny J.P. Should people taking opioids for medical reasons be allowed to work and drive?. Addiction 1996, 91(11):1581-1584.
50. Zacny J.P., Conley K., Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1997, 282(3):1187-1197.